Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M

Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug plecanatide for chronic idiopathic constipation with a new batch of upbeat Phase III data centered on irritable bowel syndrome with constipation. The study was conducted among 1,135 patients and the biotech says it will now follow up with a new application in Q1 2017. Synergy is already looking at a PDUFA date of January 29 for its first indication. The company’s shares spiked 6% on the news.

Blueprint Medicines raised $125 million through the sale of stock.

Bluebird Bio $BLUE has had to endure some considerable pain as the hype around its gene therapies gave way to some serious concerns about their limitations. But new upbeat cancer data has helped swell its sails once again, setting up a $250 million raise.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->